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Patient-specific quality assurance for intensity-modulated radiation therapy (IMRT) 
dose verification is essential. The aim of this study is to provide a new method based 
on the relative error distribution by comparing the fluence map from the treatment 
planning system (TPS) and the incident fluence deconvolved from the electronic 
portal imaging device (EPID) images. This method is validated for 10 head and 
neck IMRT cases. The fluence map of each beam was exported from the TPS and 
EPID images of the treatment beams were acquired. Measured EPID images were 
deconvolved to the incident fluence with proper corrections. The relative error 
distribution between the TPS fluence map and the incident fluence from the EPID 
was created. This was also created for a 2D diode array detector. The absolute 
point dose was measured with an ionization chamber, and the dose distribution 
was measured by a radiochromic film. In three cases, MLC leaf positions were 
intentionally changed to create the dose error as much as 5% against the planned 
dose and our fluence-based method was tested using gamma index. Absolute errors 
between the predicted dose of 2D diode detector and of our method and measure-
ments were 1.26% ± 0.65% and 0.78% ± 0.81% respectively. The gamma passing 
rate (3% global / 3 mm) of the TPS was higher than that of the 2D diode detector 
(p < 0.02), and lower than that of the EPID (p < 0.04). The gamma passing rate (2% 
global / 2 mm) of the TPS was higher than that of the 2D diode detector, while the 
gamma passing rate of the TPS was lower than that of EPID (p < 0.02). For three 
modified plans, the predicted dose errors against the measured dose were 1.10%, 
2.14%, and -0.87%. The predicted dose distributions from the EPID were well 
matched to the measurements. Our fluence-based method provides very accurate 
dosimetry for IMRT patients. The method is simple and can be adapted to any 
clinic for complex cases.
PACS numbers: 87.55.D-, 87.55.km, 87.55.Qr, 87.57.uq
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I. INTRODUCTION
The applications of intensity-modulated radiation therapy (IMRT) have progressed to various 
sites in the body to provide adequate doses to targets while sparing normal tissues. To accurately 
deliver steep dose distributions to the patient, image-guided devices such as electronic portal 
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imaging devices (EPIDs), computed tomography (CT) on-rail, infrared markers, and ultrasound 
systems have been used before or during irradiation. Although an EPID is commonly used 
during imaging to detect anatomical and field locations while conducting patient setup, these 
devices have also been used for dose verification with suitable algorithms and corrections.(1–20) 
Various groups have used EPID image conversion via deconvolution of the incident fluence 
distribution and optical glare kernel to dose distribution via the convolution kernel.(4,6,8,9) These 
approaches have provided efficient IMRT dose verification for patient-specific quality assurance 
(QA). IMRT QA is commonly verified in each patient using a two-dimensional (2D) diode or 
chamber array detector. However, Nelms et al.(21) demonstrated a poor correlation between the 
planar IMRT QA passing rates and clinically relevant patient dose errors, which may occur in 
the predicted dose distributions involving only three dimensions (3D). Kruse(22) also reported 
insensitivity between the per-beam QA gamma passing rate and dosimetric accuracy in 3D. 
These studies suggest the importance of not only evaluating dose verification in 3D over a 
clinically relevant anatomic field but also of predicting dose distributions on the basis of QA 
results,(23,24) or measurement-guided dose reconstruction (MGDR).(25) The measured data are 
usually derived from 2D or 3D detector arrays and include EPID dosimetry.(26) A few studies 
have used measured fluence data(27,28) and required dose calculation engines, such as pencil 
beam convolution algorithms, to reconstruct the 3D dose distributions.
In our previous study, the relative local error distribution in 2D was created as a per-beam 
QA for IMRT, after which the error distribution was forward-projected to the dose grid data 
of each beam to create QA results-based predicted dose distributions where prediction algo-
rithms had been validated.(24) Assuming that the relative error distribution determined in the 
phantom measurement would be maintained in air measurements and that the hypothesis is 
correct, it would likely be more efficient to perform per-beam QA under fluence verification in 
air without a dose comparison; in other words, to predict dose distribution on the basis of the 
MGDR. The aim of this study was to validate this air fluence approach for predicting IMRT 
dose distribution in 3D using EPID.
 
II. MATERIALS AND METHODS
A linear accelerator with a 6 MV X-ray beam and dose rate of 300 monitor units (MU) per min 
(ONCOR Impression PLUS; Siemens Medical Systems, Concord, CA) was used. An EPID 
(OPTIVUE 1000ST; Siemens Medical Systems) was used to acquire images comprising 1024 × 
1024 matrices, with a detector size of 0.4 × 0.4 mm2. The source-imager distance (SID) was 
set to 130 cm for all image acquisitions. A XiO treatment planning system (Elekta Instrument 
AB, Stockholm, Sweden) was used to calculate dose distributions and export a fluence map 
of each beam. The dose calculation and fluence map resolutions were 1 × 1 × 1 mm3 and 1 × 
1 mm2, respectively. The process used to convert an EPID image to incident fluence is shown 
in Fig. 1. Several necessary corrections are presented in detail in the following sections.
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A.  Correction of EPID response against the fluence map for an open field
At 130 cm, the possible image acquisition area is 315 × 315 mm2 at the isocenter plane. 
Because no additional build-up material is placed on the EPID, the horn effect, which derives 
from a flattening filter as well as the fluence map of the TPS in air, may be visible in an EPID 
image. The fluence map was defined at the isocenter plane, and the acquired EPID image was 
scaled from 130 cm to a source-axis distance of 100 cm, resulting in an EPID-derived pixel 
resolution of 0.31 mm at the isocenter plane. A fluence map of the 30 × 30 cm2 open field was 
calculated in the TPS at an irradiation dose of 10 MU to the EPID. This was selected because 
the OPTIVUE 1000ST experiences pixel variations and reduced reproducibility at doses 
< 10 MU.(18,20) Regarding the hardware correction the EPID image at 10 MU was used to cor-
rect for the combination of pixel sensitivity variations(7) and the horn effect(4,8) because the 
pixel profile created by an automatic flood-field correction in the image acquisition software 
was almost flat (data not shown). Despite the flat pixel profile, the 2D pixel sensitivity map 
(PSM) was calculated as the ratio of the off-axis pixel value to the central axis, as discussed 
by Greer.(7) After creating the PSM, a raw EPID image was calculated by multiplying the 
acquired image by the number of frames,(20) subtracting the dark current image, and dividing 
by the PSM. Regarding the TPS correction to correct the horn effect on the fluence map, both 
the fluence map and raw 30 × 30 cm2 EPID image were normalized to the central axis value, 
after which a horn correction map (HCM) was calculated by dividing the normalized raw EPID 
data by the normalized fluence map. Both PSM and HCM were used to correct the horn effect 
in hardware and software approaches. The correction is described by the following equation:
  (1)
 
Praw(i, j) = 
{( Na) – Pdark(i, j)}
PSM · HCM
n
a = 1 Pa(i, j) ×Σ
where Praw(i, j) denotes a raw pixel value at location i, j on the EPID, Pa(i, j) denotes a pixel 
value on an acquired image for the ath segment, Na denotes the number of frames for the ath 
segment, n denotes the number of segments, and Pdark(i, j) denotes a pixel value in the current 
dark image.
Fig. 1. Conversion process from the EPID image to EPID fluence.
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B.  MLC transmission fraction factor
A step-and-shoot IMRT technique was used in this study, therefore requiring that the MLC-
transmitted radiation, as well as the incident beam, should be accounted for in the irradiated 
EPID image. The OPTIVUE 1000ST comprises amorphous, indirect-type silicon detectors; 
therefore, the gadolinium oxysulfide phosphor layer, which has a high atomic number, over-
responds to low-energy X-rays transmitted from the MLC at off-axis positions relative to the 
central axis position and according to the presence of a flattening filter, as shown by Vial et 
al.(14) According to this study, the MLC transmission fraction (MTF) factor (MTFF), a function 
of the central off-axis distance via leaf movement, can be calculated from the two irradiated 
EPID images as an open field of 30 × 30 cm2, and a closed field by MLC leaves. The MTFF is 
assumed to be radially symmetrical. The off-axis distance was up to 12 cm on one side because 
the beam flat region is 80% of a 30 cm wide field. The fraction value was defined as the fraction 
of MU irradiation from the closed field against the total MU irradiation from the closed and 
open fields. For example, a fraction value of 0.1 indicates a 10 MU closed field and 90 MU 
open field. The fraction values ranged between 0.1 and 0.9 at intervals of 0.1.
According to each segment shape in each beam derived from the DICOM RT-plan file, the 
MTF factor MTFF(i, j) at each pixel location i, j on an EPID image was calculated using a 
look-up table with 2D interpolation, as functions of the fraction value and the distance from 
the beam central axis. At a fraction value of < 0.1, the MTFF(i, j) at a fraction value of 0.1 
was used. At a fraction value of > 0.9, the MTFF(i, j) at a fraction value of 0.9 was used. If the 
off-axis distance on an EPID exceeded 12 cm, the MTFF(i, j) was set to zero, indicating no 
transmission of radiation to the EPID via the MLC. Raw pixel values were corrected using the 
MTFF(i, j) as described in the following equation:
 PMTF (i, j) = Praw (i, j) × (1 + MTFF (i, j)) (2)
where PMTF (i, j) denotes a pixel value corrected using the MTFF (i, j).
C.  Phantom scatter correction on an EPID
The EPID is assumed to comprise high-density scattering material; therefore, a reference phan-
tom scatter ratio against a 10 × 10 cm2 open field is likely necessary for comparisons between a 
converted incident fluence on EPID in air and fluence maps from the TPS. First, the total scatter 
factor (Scp) was measured in square fields ranging from 2 × 2 cm
2 to 20 × 20 cm2 on EPID at 
doses of 100 MU each. The mean pixel values in the 10 pixel × 10 pixel region of interest were 
calculated in each field and normalized to the values in a reference field (10 × 10 cm2). The 
collimator scatter factors (Sc), also at field sizes of 2 × 2 cm
2 to 20 × 20 cm2, were exported 
from the TPS. On EPID, the phantom scatter factor (Sp) was calculated as the Scp divided by 
the Sc. To access the Sp at different equivalent field sizes, a second-order polynomial curve 
fit was used. A DICOM RT-plan file was used to calculate the equivalent square field size of 
each segment in IMRT. The equivalent field size was calculated as the square root of the area 
that comprised the MLC leaf opening of each segment. On raw EPID images, the pixel value 
belonging to each segment was corrected according to the Sp of the corresponding segment, 
as shown in Eq. (3): 
  (3)
 
PSc(i, j) = 
PMTF(i, j)
Sp,k
where PSc(i, j) denotes the pixel value after phantom scatter correction on an EPID, 
PMTF(i, j) denotes the corrected pixel value calculated from Eq. (2), and Sp,k denotes the phantom 
scatter factor for the kth segment.
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D.  Deconvolution of the dose glare kernel on EPID
As the OPTIVUE 1000ST is an indirect-type flat panel detector, incident photon irradiation of the 
EPID generates optical scatter at the amorphous silicon layer and generates dose deposition.(6) 
To convert the EPID image to the incident fluence in air, both optical and phantom scatter must 
be removed. The measured EPID image, corrected as described above, was deconvolved to the 
incident fluence according to the deconvolution of the combined optical and dose glare kernel, 
as proposed by Warkentin et al.(4) The optical and dose glare kernel, Kglare(r), as a function of 
the radial distance r cm from the beam central axis, is used in the following equation:
 Kglare(r) = e
–C1r + C2e
–C3r (4)
The parameters C1, C2, and C3 are empirically derived fitting coefficients between the fluence 
map and raw EPID image at a 10 × 10 cm2 open field. These values were 30 cm−1, 0.046, and, 
2.7 cm−1 for C1, C2, and C3, respectively. Using Eq. (4), the PSci, j) was deconvolved by the 
following equation:
 PEPID fluence(i, j) = PSc(i, j) ⊗ Kglare(r) (5)
where PEPID fluence(i, j) denotes the pixel value after the deconvolution of Kglare(r), which results 
in an incident fluence.
E.  Pixel value to MU conversion
Renner et al.(6) described a method for pixel correction. Briefly, the corrected pixel value is 
converted to a relative monitor unit (RMU) using a calibration curve generated between the pixel 
value and MU. The TPS fluence map provides a relative number with respect to a collimator 
scatter factor of 1.0 in a 10 × 10 cm2 field; therefore, the calibration curve was measured on an 
EPID on the same field size, with MUs ranging from 10 to 100 MU. The curve fitting function 
was created from the correlation between the corrected pixel value and MU and was used to 
convert corrected pixel values to the RMUs.
F.  Predicted dose reconstruction from the measured data
Two predicted dose patterns were reconstructed from the measured QA data. One pattern was 
based on a fluence comparison between the TPS fluence map and measured corrected EPID 
fluence. The other pattern was based on a dose comparison between the calculated TPS dose 
distribution and the measured 2D diode array dose distribution (MapCHECK; Sun Nuclear 
Corporation, Melbourne, FL). The details of our predicted dose reconstruction method have 
been reported elsewhere.(24) The dose reconstruction process in this study differs from that of 
the previous study with respect to the error map creation step. To reiterate, a fluence comparison, 
rather than a dose comparison, was performed to create the error map. However, a dose com-
parison was also performed as a reference. The relative error map was assumed to remain the 
same between the fluence comparison and dose comparison during comparisons of calculated 
and measured values (i.e., fluence in air or doses in a water equivalent phantom).
Ten head and neck cancer patients who underwent IMRT via fixed gantry step-and-shoot 
delivery were selected for this study. First, each treatment plan (2 Gy/fraction) was developed; 
for cases in which the MU of a specified segment received less than 10 MU, the prescribed 
dose of 2 Gy was rescaled to each segment MU exceeding 10 MU because of the unstable 
linearity and repeatability of EPID.(18,20) For fluence comparison, the fluence map for each 
beam was exported from the TPS, and the EPID image for each beam was acquired using the 
same MU and gantry angle as the treatment plan. To correct for EPID sag and translation at 
the treatment gantry angle with respect to the beam central axis, a reticle plate, in which two 
orthogonal tungsten wires were matched to the beam central axis, was inserted to the shadow 
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tray followed by irradiation to the EPID. The sag and translation offset value correction for 
the EPID was recorded and used to match the EPID image to the beam central axis.(29) The 
measured EPID image for each beam was converted to an image using Eqs. (1) to (5), followed 
by pixel-to-MU conversion.
To create an error map between the TPS and MU-converted EPID fluence, the fluence map 
location with the maximum fluence value was used as a normalization point from which to scale 
the EPID fluence map according to the method described by Partridge et al.,(30) as a comparison 
between the fluence map and EPID fluence in air. In contrast, to create an error map between 
the TPS dose plane and the measured dose in each beam, a 2D diode array was placed on the 
treatment couch, followed by beam irradiation at gantry 0. The source-to-detector distance was 
set at 100 cm, and the depth was set at 5 cm. The calculated dose distribution in the coronal 
plane at a depth of 5 cm was exported from the TPS and compared with the measured data to 
create an error map. The resolution of both the fluence map and EPID fluence was 1 × 1 mm2 
as a result of resampling with a pixel interval of 0.31 mm at the isocenter plane. Using the 
commercial software interpolation function, the resolutions of the calculated dose plane and 2D 
diode array were 1 × 1 mm2 and 5 × 5 mm2, respectively. For each beam, the error maps for the 
fluence comparison and dose comparison were incorporated into the 3D dose grid, which had 
been exported from the TPS in DICOM RT-dose format, to create the predicted dose distribution.
G.  Validation of the predicted dose and dose distribution
Predicted dose validation was performed in ten head and neck cancer patients. Absolute dose 
measurements and dose distributions in the axial plane were verified using an ionization cham-
ber and EBT-film, respectively. A water-equivalent phantom and ionization chamber (PTW 
PinPoint 31016 chamber; PTW, Freiburg, Germany) were used to measure absolute doses. A 
verification phantom (I’mRT phantom; IBA Dosimetry GmbH, Schwarzenbruck, Germany) and 
radiochromic film (EBT2; Ashland Specialty Ingredients, Wayne, NJ) inserted in the isocenter 
plane were used for film verification. One location in the high-dose and low-dose gradient 
regions was selected for dose measurement.
For three patients, the MLC leaf positions were manually modified to create plans with dose 
errors. Other machine parameters (e.g., gantry angle, collimator angle, and MU in each seg-
ment) remained the same as in the original plan. The predicted doses reconstructed from the 
EPID measurement-based and 2D diode array measurement-based error maps were compared 
with the measured data; the absolute dose and dose distribution as measured using film were 
used as references. Three film verification evaluations were performed: relative dose differ-
ence, distance to agreement (DTA), and gamma evaluation pass rate (criteria: 3% global / 3 
mm, 2% global / 2 mm with a lower threshold value of 10%).(31) A paired t-test was used for 
comparison. Statistical significance was set at a 5% level.
 
III. RESULTS 
MTFF(i, j), as a function of the distance from the beam central axis, is shown in Fig. 2. Each 
curve was fitted via polynomial regression. This factor increases according to an increase in the 
fraction value. The collimator scatter factor (Sc), total scatter factor (Scp) on an EPID, and phan-
tom scatter factor (Sp) on an EPID are shown in Fig. 3. Figure 4 presents MUs versus corrected 
pixels on an EPID curve. Linearity was observed with a good correlation coefficient of 0.9999.
The predicted doses derived from the 2D diode detector dose comparison and EPID fluence 
comparison were calculated and compared with the doses measured in an ionization chamber. 
The absolute errors for both prediction methods in the 10 study cases are presented in Fig. 5; 
these errors were 1.26 ± 0.65% and 0.78 ± 0.81% for the dose and fluence comparisons, 
respectively. Although the fluence comparison had a smaller error than the dose comparison, 
this difference was not significant.
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The predicted dose distributions derived from the 2D diode detector dose comparison and 
EPID fluence comparison were calculated and compared with the dose distribution measured 
on film. As a reference, the TPS dose distribution was also compared with the measured dose 
distribution. As shown in Fig. 6, the gamma passing rates at the criteria of 3% global / 3 mm 
were 90.35% ± 6.88%, 84.78% ± 8.02%, and 93.15% ± 4.36% for the TPS, 2D diode detector, 
Fig. 2. MLC transmission fraction factor (MTFF) as a function of the distance from the beam central axis.
Fig. 3. The scatter factors Sc, Scp, and Sp as functions of the square fields derived from the EPID.
Fig. 4. Calibration curve for OPTIVUE 1000ST. Corrected pixels were plotted against monitor units (MUs). A linear 
fitting formula was used for the conversion from pixel values to MUs.
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and EPID, respectively. The TPS gamma passing rate was higher than that of the 2D diode 
detector (p < 0.02) but lower than that of the EPID (p < 0.04). For the criteria of 2% global / 
2 mm, the gamma passing rates were 71.93% ± 13.35%, 67.97% ± 11.92%, and 78.94% ± 9.77% 
for the TPS, 2D diode detector, and EPID, respectively. Although the TPS gamma passing rate 
was higher than that of the 2D diode detector, this difference was not significant. In contrast, 
the TPS gamma passing rate was lower than the EPID rate (p < 0.02).
The original planned doses without leaf position modifications, modified planned doses 
with altered leaf positions, predicted doses, and measured doses for three cases are shown in 
Table 1. By intentionally changing the MLC leaf positions of three cases, the modified planned 
doses differed from the original planned doses by as much as -6.47%,   -7.07%, and -8.03%. 
The predicted dose errors against the measured doses were 1.10%, 2.14%, and -0.87%. As the 
respective measured dose errors against the modified planned doses were -1.66%, -0.24%, and 
-0.57%, the respective predicted dose errors against the modified planned doses were -0.58%, 
1.90%, and -1.44%.
Regarding dose distribution verification, the gamma passing rates between the original 
plans and film measurement from the modified plans for these three cases at the criteria of 3% 
global / 3 mm were 86.64%, 73.07%, and 76.50%. In contrast, the respective gamma passing 
rates between the predicted dose distributions and films in the same sequence were 96.88%, 
97.49%, and 92.31%. Using the criteria of 2% global / 2 mm criteria, the gamma passing rates 
between the TPS and film were 74.39%, 55.84%, and 56.41%. In contrast, the respective gamma 
Fig. 5. Absolute percent error against the measured dose for the 2D diode detector and EPID. Error bars represent 1 SD. 
There was no significant (NS) difference.
Fig. 6. Comparisons of the gamma passing rates (criteria: 3% global / 3 mm, 2% global / 2 mm) for the calculated dose 
distribution of the TPS and predicted dose distributions of the 2D diode detector and EPID, compared with the film 
measurement. Each bar indicates the mean gamma passing rate; error bars represent 1 SD. * = p < 0.02, † = p < 0.04, 
NS = not significant.
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passing rates between the predicted dose distributions and films were 88.88%, 90.10%, and 
73.16%. The predictions improved the gamma passing rates using both criteria. Representative 
dose differences, DTA distributions, and gamma distributions (3% global / 3 mm) in the axial 
plane from one of the cases are shown in Fig. 7.
Following manual leaf modification to the original plan, a dose error near -5% between the 
modified plan and original plan was achieved, as shown in Fig. 7(a). In contrast, the predicted 
dose distribution more closely matched the measured dose distribution shown in Fig. 7(d). 
The DTA distribution for the predicted distribution also provided a closer match, as shown in 
Fig. 7(e), when compared with the original distribution in Fig. 7(b). Gamma values of < 1 and 
> 1 are presented in white and red, respectively. The predicted gamma distribution was better 
than the original distribution. The gamma passing rates at the criteria of 3% global / 3 mm were 
96.88% in Fig. 7(f) and 86.64% in Fig. 7(c).
 
Table 1. Comparisons of the predicted and measured doses.
      Predicted  Measured
      Dose Predicted Dose
      Error Dose Error
      Against Error Against
  Original Modified   Modified Against Modified
  Planned Planned Predicted Measured Measured Planned Planned
  Dose Dose Dose Dose Dose Dose Dose
 Case (Gy) (Gy) (Gy) (Gy)  (%) (%) (%)
 1 3.09 2.89 2.87 2.84 -0.58 1.10 -1.66
 2 4.10 3.81 3.88 3.80 1.90 2.14 -0.24
 3 3.61 3.32 3.27 3.30 -1.44 -0.87 -0.57
Fig. 7. Comparisons of the dose difference (a), distance to agreement distribution (b), and gamma distribution (c) for the 
original planned dose vs. the measured film from one of the three modified plans. The predicted dose vs. measured data 
are shown in (d), (e), and (f), respectively. Gamma index values of > 1 are shown in red.
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IV. DISCUSSION
The relative error distribution between the fluence map calculated by the TPS and the measured 
fluence map deconvolved from an EPID image was used to predict doses on the basis of per-
beam QA results. Although other approaches to dose prediction exist, these have incorporated 
2D or 3D diode array detectors(32) for dose measurement and even the fluence measurements 
in air,(28) resulting in converted doses from dose calculations using beam data such as the tis-
sue phantom ratio and off-center ratio. In this study, the relative error distribution in air was 
assumed to be the same value as that for a phantom in the same situation when comparing 
calculations and measurements. In a previous study, the relative error distribution in each beam 
was determined from water-equivalent material.(24) Several researchers have deconvolved EPID 
images into primary fluence and subsequently into doses;(4,6,8,9) although corrections through-
out the conversion process are necessary, our approach to fluence comparison is considered 
an intermediate state in other conversion approaches. If our hypothesis were correct, the same 
relative error distribution determined via fluence comparison would be obtained even in an 
air comparison. Therefore, the fluence comparison results for each beam were incorporated 
into the original dose determined from the DICOM RT-dose data, and the predicted dose was 
reconstructed without dose calculation.
For MTFF(i, j) measurements, the maximum off-axis distance from the central axis was 
12 cm. The MTF fraction values ranged from 0.1 to 0.9. In all 10 cases, both the maximum 
upper jaw opening size and MLC leaf opening size were within 20 cm. Hence, the maximum 
off-axis distance of 12 cm was satisfied by the correction. However, according to the leaf 
sequence in step-and-shoot IMRT, some pixels may have values of < 0.1 or > 0.9, resulting in 
correction errors. In particular, a fraction value of > 0.9 indicates a region wherein most MLC 
leaves on an EPID were closed (covered) during irradiation. Such a region may correspond 
to areas outside of the field and above normal tissues with relatively lower dose constraints 
against the target (e.g., spinal cord).
When comparing predicted and measured doses, the mean difference of 0.78% for the fluence 
comparison was smaller than that of 1.26% for dose comparison, although this difference was 
not significant. Both predicted doses corresponded well to the measured dose.
Regarding dose distribution verification, the mean gamma passing rate for the EPID at criteria 
of 3% global / 3 mm was 93.2%. Although this value may not be high in comparison with the 
huge amount of film verification QA results published by Pulliam et al.,(33) those authors stated 
that a gamma passing rate under the criteria of 5% global / 3 mm should exceed 90%. The criteria 
used in our study with respect to dose differences were stricter than those used in the earlier 
study. According to a survey of planar IMRT QA analysis by Nelms and Simon,(34) a gamma 
passing rate under the criteria of 3% global/3 mm should generally range from 90% to 95%.
In our previous study, dose prediction algorithms were validated through film verification. The 
gamma passing rate under the criteria of 3% global / 3 mm was 86.9%.(24) Figure 8 shows the 
differences between the TPS dose (a) and 2D diode detector (b) and EPID predicted doses (c), 
when compared with film measurements. As shown in Figs. 8(a), (b), and (c), inhomogeneous 
distribution, possibly caused by the inherent film artifacts, was observed even in the region of 
homogeneous dose irradiation inside the green isodose line. Hence, the mean gamma passing 
rate of 93.2% was not worse than that obtained through film verification.
The mean gamma passing rates under the criteria of 3% global / 3 mm were lower for the 
2D diode detector than for the TPS and EPID. In particular the rates obtained with the 2D 
diode detector and EPID were 84.8% and 93.2%, respectively. Despite using the same dose 
prediction approach, the hypothesis that the relative error maps would be the same in air 
and in the phantom was invalid. Differences in the gamma passing rates may have resulted 
from the resolution and data interpolation method associated with the 2D diode detector. The 
data resolutions were 1 mm, 0.31 mm, and 5 mm for the TPS, EPID, and 2D diode detector, 
respectively. Regarding the latter detector, the 5-mm resolution used in this study was  available 
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in the “Dose Interpolated” data section of the MapCHECK software package. The gamma 
distributions under the criteria of 3% global / 3 mm are shown in Figs. 8(d), (e), and (f). The 
respective gamma passing rates were 96.66%, 86.40%, and 95.94%. The high-dose regions 
(inside the green isodose line) of the predicted and measured doses were matched within a 5% 
dose difference, whereas in other regions, the gamma index exceeded 1, as shown in red along 
the lateral edge of the green isodose line in Fig. 8(e). These regions were derived from dose 
interpolation (MapCHECK software) at a detector interval of 10 mm, rather than 5 mm, at an 
off-axis distance of > 5 cm, which comprises a standard diode detector configuration. For head 
and neck IMRT, the field width along the leaf motion was relatively wider than that of prostate 
IMRT. Sumida et al.(24) reported a dose prediction algorithm and validation for prostate IMRT. 
However, if this algorithm is used for relatively large targets such as head-and-neck and pelvic 
cancers, the detector resolution should be finer than the standard resolution of the MapCHECK 
device to compensate for the software interpolated data. A finer resolution can be achieved using 
the doubled detector density method, as suggested by Keeling et al.(35)
One limitation of this study was the requirement for MU in each segment to exceed 10 MU 
because the OPTIVUE 1000ST exhibits pixel variations and reduced reproducibility below 
MU.(18,20) Therefore, MU scaling was incorporated to solve this issue. Given the improve-
ments in image acquisition software produced by another vendor, rather than in the EPID,(18) 
the concept of fluence comparison adopted in this study would be expected to predict doses 
even for rotational IMRT. Another limitation of this study was the normalization of the incident 
fluence, which was deconvolved from the EPID image, to match the TPS fluence map. As the 
peak fluence map value depends on the MLC leaf sequence pattern and MU, if the peak value 
location is in a small area, a systematic error in the normalization process may occur because 
of the measurement accuracy of the EPID output factor in small fields. In the future, an abso-
lute comparison will be needed to create a relative error map, thus improving the accuracy of 
correction to EPID.
Currently, the dose prediction approach could be used in IMRT QA to compare delivered 
and planned dose volume indices from dose-volume histograms and doses. Although validation 
of point doses in 1D and dose distributions in 2D is possible, it would be difficult to validate 
Fig. 8. Comparisons of dose differences for the planned dose distribution (a), and the predicted dose distributions of the 
2D diode detector (b) and EPID (c). Comparisons of gamma distribution are also shown in (d), (e), and (f), respectively. 
Gamma index values of > 1 are shown in red.
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dose-volume data, as a high-detector density is required for 3D measurements. In future, 3D 
dosimeters such as gel dosimeters(36) and plastic scintillation detectors(37) should be used to 
validate dose-volume data.
When EPID-based per-beam QA is performed as a patient-specific QA to predict the dose 
in a patient, radiation damage to the system is a concern with respect to the lifespan of the 
EPID. Louwe et al.(38) reported that some EPIDs exhibited excellent stability for periods up to 
23 months, whereas other EPIDs required more frequent replacement.
 
V. CONCLUSIONS
Dose predictions were based on fluence comparisons between TPS fluence maps and incident flu-
ence deconvolved from EPID images. For validation, the measured doses and dose distributions 
were compared with the corresponding predicted values. The absolute percent errors against the 
measured doses were < 1% for fluence-based dose predictions. To verify dose distributions, the 
gamma passing rates for fluence-based values were higher than those for TPS values under the 
criteria of 3% global / 3 mm or 2% global / 2 mm. This dose prediction approach is, therefore, 
useful and efficient with respect to EPID image collection and fine spatial resolution.
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